Share on StockTwits

Shares of OraSure Technologies (NASDAQ:OSUR) have received an average rating of “Hold” from the eight ratings firms that are currently covering the company, American Banking News.com reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $8.93.

Several analysts have recently commented on the stock. Analysts at Raymond James raised their price target on shares of OraSure Technologies from $8.50 to $9.00 in a research note on Thursday. Separately, analysts at Canaccord Genuity raised their price target on shares of OraSure Technologies from $10.00 to $11.00 in a research note on Thursday. They now have a “buy” rating on the stock. Finally, analysts at Mizuho raised their price target on shares of OraSure Technologies from $9.00 to $10.00 in a research note on Wednesday. They now have a “buy” rating on the stock.

OraSure Technologies (NASDAQ:OSUR) traded up 0.13% on Thursday, hitting $7.49. 496,652 shares of the company’s stock traded hands. OraSure Technologies has a 52-week low of $3.75 and a 52-week high of $8.60. The stock’s 50-day moving average is $6.45 and its 200-day moving average is $6.66. The company’s market cap is $418.2 million.

OraSure Technologies (NASDAQ:OSUR) last announced its earnings results on Wednesday, May 7th. The company reported ($0.10) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.13) by $0.03. The company had revenue of $23.50 million for the quarter, compared to the consensus estimate of $23.28 million. During the same quarter last year, the company posted ($0.18) earnings per share. OraSure Technologies’s revenue was up 10.8% compared to the same quarter last year. On average, analysts predict that OraSure Technologies will post $-0.23 earnings per share for the current fiscal year.

OraSure Technologies, Inc, is engaged in development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using the Company’s oral fluid technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.